<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Anti-GPC3 development is shifting to CAR-T, TCR, T-cell engagers and radiopharmaceuticals, creating opportunities in HCC, NSCLC and other GPC3-positive tumors.Dublin, Sept. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/6274324/anti-gpc3-targeted-therapies-target?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ngkkfc&amp;utm_campaign=2350074+-+Anti-GPC3+Targeted+Therapies+Market+Poised+for+Growth+Through+2040+as+Expanding+Patient+Populations+and+Competitive+Innovation+Unlock+New+Opportunities&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Anti-GPC3 Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2040">"Anti-GPC3 Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2040"</a> has been added to ResearchAndMarkets.com's offering. The "Anti-GPC3 Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2040" report provides a comprehensive analysis of the evolving anti-GPC3 targeted therapies market across the United States, EU4 countries comprising Germany, France, Italy, and Spain, the United Kingdom, and Japan. Covering the 2022-2040 study period, the report examines epidemiology, treatment practices, emerging therapies, competitive dynamics, patient eligibility, drug uptake, market access, and long-term revenue opportunities. Key Market Highlights <ul><li>Glypican-3 (GPC3) has emerged as a highly cancer-specific therapeutic target, particularly in hepatocellular carcinoma (HCC). Limited efficacy from earlier anti-GPC3 monotherapies has accelerated the development of next-generation approaches, including CAR-T cells, T-cell receptor-engineered therapies, T-cell engagers, bispecific and trispecific antibodies, and radiopharmaceuticals.</li><li>HCC represents the primary indication within the anti-GPC3 targeted therapies landscape, while non-small cell lung cancer (NSCLC), gastric cancer, Merkel cell carcinoma, myxoid/round cell liposarcoma, and other GPC3-expressing tumors may create additional clinical and commercial opportunities.</li><li>Leading anti-GPC3 therapy developers include Eureka Therapeutics, AstraZeneca, Bayer, CRISPR Therapeutics, BeOne Medicines, Zymeworks, RayzeBio, Carisma Therapeutics, Moderna, and other oncology-focused companies.</li><li>Market growth is expected to be supported by increasing cancer incidence, greater use of biomarker-guided treatment, expanding clinical pipeline activity, and anticipated regulatory approvals through 2040.</li></ul> GPC3 Targeted Therapy Landscape GPC3 is highly expressed in malignant liver cells while showing limited or no expression in healthy hepatic tissue, making it a compelling molecular target for selective cancer treatment. Its tumor-specific expression profile may support targeted immune activation and drug delivery while reducing damage to non-cancerous tissue. HCC remains the leading focus of GPC3-targeted drug development. Major risk factors associated with HCC include chronic alcohol use, hepatitis B or C infection, obesity- and diabetes-associated nonalcoholic steatohepatitis, primary biliary cholangitis, haemochromatosis, and alpha-1 antitrypsin deficiency. NSCLC is also gaining attention within the anti-GPC3 therapies market. It accounts for approximately 85% of lung cancer cases and includes adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, and sarcomatoid carcinoma. GPC3 expression in selected NSCLC populations may enable biomarker-led development strategies, particularly in squamous disease. Anti-GPC3 Targeted Therapies Epidemiology The report evaluates historical and forecast epidemiology across the seven major markets, including total cases in selected indications, GPC3-eligible patient populations, and treated cases. In 2025, GPC3 expression was estimated at approximately 75% in HCC, around 70% in Merkel cell carcinoma, approximately 45% in squamous NSCLC, and nearly 33% in myxoid/round cell liposarcoma. HCC represented the largest GPC3-expressing population in the seven major markets in 2025, with approximately 80,000 cases. The EU4 and the United Kingdom recorded about 40,000 incident HCC cases, while the United States and Japan each recorded approximately 33,000 cases. Japan accounted for an estimated 25,000 GPC3-expressing HCC cases, reinforcing the country's importance for clinical development and commercialization. Emerging Anti-GPC3 Therapies BeOne Medicines is evaluating BGB-B2033, a bispecific antibody designed to activate 4-1BB signaling on CD8-positive T cells in the presence of GPC3-positive tumor cells. The candidate is being studied alone and in combination with tislelizumab in a Phase I program covering advanced or metastatic HCC, AFP-producing gastric cancer, extragonadal yolk sac tumors, nondysgerminomas, and GPC3-positive squamous NSCLC. AstraZeneca's AZD9793 is a trispecific IgG1 monoclonal antibody and CD8-targeted T-cell engager designed to connect tumor-infiltrating T cells with GPC3-positive cancer cells. AstraZeneca presented data at ASCO 2025 from RHEA-1, the first-in-human study of AZD9793 in advanced GPC3-positive HCC. Other notable pipeline programs include Eureka Therapeutics' ECT204 CAR-T therapy, Bayer's actinium-225 GPC3 radiopharmaceutical, CRISPR Therapeutics' RPCAR01 engineered cell therapy, Zymeworks' ZW251, and RayzeBio's RYZ811 and RYZ801 theranostic pair. Recent Anti-GPC3 Market Developments <ul><li>In January 2026, the US Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to ECT204 for advanced HCC.</li><li>At the 2026 ASCO Gastrointestinal Cancers Symposium, RayzeBio presented the design of the ongoing Phase I/IIb RYZ801-101 study evaluating RYZ811 and RYZ801 in previously treated, unresectable GPC3-positive HCC.</li><li>Zymeworks presented the design of its first-in-human, multicenter Phase I trial evaluating ZW251 in advanced HCC at the 2026 ASCO Gastrointestinal Cancers Symposium.</li></ul> Anti-GPC3 Targeted Therapies Market Outlook The anti-GPC3 targeted therapies market is positioned for continued expansion as clinical evidence matures and developers refine patient-selection strategies. Multiple therapeutic modalities could address limitations associated with earlier anti-GPC3 monotherapy, including insufficient tumor saturation and variable expression across cancer types. The report assesses anticipated drug launches and uptake from 2026 through 2040, along with market share, pricing, reimbursement, accessibility, and country-specific commercialization considerations. It also reviews pipeline candidates across Phase I, Phase II, and Phase III development, as well as licensing agreements, collaborations, mergers and acquisitions, patents, and regulatory activity. Report Scope and Strategic Insights <ul><li>Historical and forecast anti-GPC3 targeted therapies market size through 2040</li><li>GPC3-positive target populations and indication-specific epidemiology</li><li>Current treatment practices, clinical algorithms, and unmet medical needs</li><li>Competitive analysis of approved, emerging, and pipeline therapies</li><li>Drug uptake, market share, pricing, and forecast assumptions</li><li>SWOT analysis covering clinical, commercial, and geographic factors</li><li>Market access, reimbursement, affordability, and patient-support programs</li><li>Insights from more than 10 key opinion leaders across the seven major markets</li></ul> Expert input includes perspectives from specialists associated with organizations such as the University of Miyazaki, University of Pittsburgh Medical Center, Ochsner Lafayette General Medical Center, National Cancer Center, and Memorial Sloan Kettering Cancer Center. These insights help validate treatment patterns, adoption expectations, therapy-switching considerations, accessibility challenges, and future unmet needs. Reasons to Purchase the Report <ul><li>Develop evidence-based strategies using detailed analysis of anti-GPC3 market trends and competitive dynamics.</li><li>Identify high-growth indications and geographic opportunities across the United States, Europe, the United Kingdom, and Japan.</li><li>Evaluate emerging competitors, therapeutic modalities, clinical milestones, and potential market leaders.</li><li>Assess country-specific reimbursement policies, access barriers, pricing considerations, and patient assistance programs.</li><li>Understand physician perspectives on treatment acceptance, compliance, accessibility, and adoption.</li><li>Strengthen clinical development, market entry, portfolio planning, and product launch strategies through detailed unmet-need analysis.</li></ul> As GPC3-targeted oncology research advances, clinical readouts and regulatory decisions are expected to clarify the role of these therapies in HCC, NSCLC, gastric cancer, and other biomarker-selected malignancies. The report offers a strategic view of the anti-GPC3 targeted therapies market and the opportunities likely to shape its development through 2040. Key Topics Covered: 1. Key Insights 2. Report Introduction 3. Executive Summary of Anti-GPC3 Targeted Therapies 4. Key Events 5. Epidemiology Market Forecast Methodology of Anti-GPC3 Targeted Therapies 6. Anti-GPC3 Targeted Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2040 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2040 7. Anti-GPC3 Targeted Therapies: Background and Overview 7.1. Introduction 7.2. Potential of Anti-GPC3 Targeted Therapies in Different Indications 7.3. Clinical Applications of Anti-GPC3 Targeted Therapies 8. Target Patient Pool of Anti-GPC3 Targeted Therapies 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM 8.5. Total Treatable Cases in Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM 9. Emerging Anti-GPC3 Targeted Therapies 9.1. Key Competitors 9.2. ECT204: Eureka Therapeutics 9.2.1. Product Description 9.2.2. Other Developmental Activities 9.2.3. Clinical Development 9.2.4. Safety and Efficacy 10.2.5. Analyst Views 9.3. AZD9793: AstraZeneca 9.3.1. Product Description 9.3.2. Other Developmental Activities 9.3.3. Clinical Development 9.3.4. Safety and Efficacy 10.3.5. Analyst Views List to be continued in the report 10. Anti-GPC3 Targeted Therapies: 7MM Analysis 10.1. Key Findings 10.2. Market Outlook of Anti-GPC3 Targeted Therapies 10.3. Conjoint Analysis of Anti-GPC3 Targeted Therapies 10.4. Key Market Forecast Assumptions of Anti-GPC3 Targeted Therapies 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of Anti-GPC3 Targeted Therapies by Indications in the 7MM 10.6. The United States 10.6.1. Total Market Size of Anti-GPC3 Targeted Therapies in the United States 10.6.2. Market Size of Anti-GPC3 Targeted Therapies by Indication in the United States 10.6.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of Anti-GPC3 Targeted Therapies in EU4 and the UK 10.7.2. Market Size of Anti-GPC3 Targeted Therapies by Indications in EU4 and the UK 10.7.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of Anti-GPC3 Targeted Therapies in Japan 10.8.2. Market Size of Anti-GPC3 Targeted Therapies by Indications in Japan 10.8.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. Analyst's Capabilities 17. Disclaimer 18. About the Publisher List of Tables Table 1: Target Population in the 7MM (2022-2040) Table 2: Marketed Drug Key cross Table 3: Product 1, Clinical Trial Description, 2025 Table 4: Product 2, Clinical Trial Description, 2025 Table 5: Emerging Drug Key cross Table 6: Product 1, Clinical Trial Description, 2025 Table 7: Product 2, Clinical Trial Description, 2025 Table 8: Total Anti-GPC3 Targeted Therapies Market Size in the 7MM (2022-2040) Table 9: Anti-GPC3 Targeted Therapies Market Size by Therapies in the 7MM (2022-2040) Table 10: Anti-GPC3 Targeted Therapies Market Size by Indication in the 7MM (2022-2040) Table 11: Total Anti-GPC3 Targeted Therapies Market Size in the United States (2022-2040) Table 12: Anti-GPC3 Targeted Therapies Market Size by Therapies in the United States (2022-2040) Table 13: Total Anti-GPC3 Targeted Therapies Market Size in EU4 and the UK (2022-2040) Table 14: Anti-GPC3 Targeted Therapies Market Size by Therapies in EU4 and the UK (2022-2040) Table 15: Total Anti-GPC3 Targeted Therapies Market Size in Japan (2022-2040) Table 16: Anti-GPC3 Targeted Therapies Market Size by Therapies in Japan (2022-2040) List of Figures Figure 1: Target Population in the 7MM (2022-2040) Figure 2: Total Anti-GPC3 Targeted Therapies Market Size in the 7MM (2022-2040) Figure 3: Anti-GPC3 Targeted Therapies Market Size by Therapies in the 7MM (2022-2040) Figure 4: Anti-GPC3 Targeted Therapies Market Size by Indication in the 7MM (2022-2040) Figure 5: Total Anti-GPC3 Targeted Therapies Market Size in the United States (2022-2040) Figure 6: Anti-GPC3 Targeted Therapies Market Size by Therapies in the United States (2022-2040) Figure 7: Total Anti-GPC3 Targeted Therapies Market Size in EU4 and the UK (2022-2040) Figure 8: Anti-GPC3 Targeted Therapies Market Size by Therapies in EU4 and the UK (2022-2040) Figure 9: Total Anti-GPC3 Targeted Therapies Market Size in Japan (2022-2040) Figure 10: Anti-GPC3 Targeted Therapies Market Size by Therapies in Japan (2022-2040) A selection of companies mentioned in this report includes, but is not limited to: <ul><li>Eureka Therapeutics</li><li>AstraZeneca</li><li>Bayer</li><li>CRISPR Therapeutics</li><li>BeOne Medicines</li><li>Carisma Therapeutics/Moderna</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274324/anti-gpc3-targeted-therapies-target?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ngkkfc&amp;utm_campaign=2350074+-+Anti-GPC3+Targeted+Therapies+Market+Poised+for+Growth+Through+2040+as+Expanding+Patient+Populations+and+Competitive+Innovation+Unlock+New+Opportunities&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/eq8v4w</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YzRhMmNiOTUtZjJkNS00MWQ1LWE1MTUtMDI4OWVkZTk0YmRjLTEwMjY3MzctMjAyNi0wOS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Anti-GPC3 Targeted Therapies Market Poised for Growth Through 2040 as Expanding Patient Populations and Competitive Innovation Unlock New Opportunities

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn